TITLE

Advances in Myelodysplastic Syndrome: Nursing Implications of Azacitidine

AUTHOR(S)
Demakos, Erin P.; Linebaugh, Jeanette A.
PUB. DATE
August 2005
SOURCE
Clinical Journal of Oncology Nursing;Aug2005, Vol. 9 Issue 4, p417
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, leading to bone marrow failure and peripheral blood cytopenias. MDS is difficult to diagnose because of the absence of symptoms in the early stage of the disease; it often is discovered accidentally during routine physical examinations or blood tests. The U.S. Food and Drug administration approved azacitidine (Vidaza�, Pharmion Corporation, Boulder, CO) for the treatment of MDS. Prior to the approval of azacitidine, no approved therapies were available for the treatment of MDS. Azacitidine is believed to exert its anticancer effects by induction of hypomethylation and cytotoxicity. In clinical studies, the most common adverse events during treatment with azacitidine included nausea, anemia, thrombocytopenia, vomiting, pyrexia, leukopenia, diarrhea, fatigue, injectionsite erythema, constipation, neutropenia, and ecchymosis. To ensure proper treatment with azacitidine, nurses should have an understanding of dosage and administration guidelines, commonly observed adverse events, monitoring and care of adverse events, and monitoring of laboratory tests. Having a comprehensive understanding of MDS, its underlying disease characteristics, and current treatments will enable oncology nurses to provide optimal patient care.
ACCESSION #
17909103

 

Related Articles

  • Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes. Zwierzina, H; Anderson, J E; Rollinger-Holzinger, I; Torok-Storb, B; Nuessler, V; Lyman, S D // Leukemia (08876924);Apr99, Vol. 13 Issue 4, p553 

    Myelodysplastic syndromes (MDS) caused by a clonal hematopoietic stem cell disorder progress to either overt leukemia or cytopenia, which leads to lethal infection or bleeding. Although several clinical trials have attempted to reverse cytopenia by using hematopoietic growth factors (HGF),...

  • Management of Myelodysplastic Syndromes. Larson, Richard A. // Annals of Internal Medicine;Jul85, Vol. 103 Issue 1, p136 

    Editorial. Focuses on the management of myelodysplastic syndromes, heterogeneous group of hematopoietic stem cell disorders characterized by anemia, neutropenia or thrombocytopenia. Diagnosis of the disorder based on the finding of characteristic morphologic abnormalities in the peripheral...

  • Immunomodulatory Drugs (IMiDs�): A New Treatment Option for Myelodysplastic Syndromes. Kale, Vishakha; List, Alan F. // Current Pharmaceutical Biotechnology;Oct2006, Vol. 7 Issue 5, p339 

    The IMiDs� represent a new proprietary class of thalidomide analogues that possess greater potency and less toxicity than the parent compound. As a group, these agents share the pharmacologic property of modulating cellular response to ligand activation, the precise biologic effect of which...

  • Prognostic Factors in Myelodysplastic Syndromes. TRIANTAFYLLIDIS, Irina; CIOBANU, Anca; STANCA, Oana; LUPU, Anca Roxana // Maedica - a Journal of Clinical Medicine;2012, Vol. 7 Issue 4, p295 

    Background: Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cell and are characterized by ineffective hematopoiesis with normo- or hyper cellular bone marrow and cytopenia(s). The natural evolution of the disease consists of bone marrow failure (leading to infectious...

  • An Update on the Treatment of Myelodysplastic Syndromes. Kurtin, Sandra E.; Demakos, Erin P. // Clinical Journal of Oncology Nursing;Jun2010, Vol. 14 Issue 3, pE29 

    Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal disorders of myeloid hematopoietic stem cells affecting about 300,000 people worldwide. Ineffective hematopoiesis and clonal proliferation result in significant cytopenias in affected individuals. Patients are categorized into...

  • Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS. Harada, Hironori; Harada, Yuka; Kimura, Akiro // Current Cancer Drug Targets;Sep2006, Vol. 6 Issue 6, p553 

    Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells characterized by ineffective and inadequate hematopoiesis. MDS is also a susceptibility to acute myeloid leukemia (AML) and shown to be extremely resistant to current therapeutic strategies. MDS in a subset of 10-20%...

  • Pre-progenitor cells: a proposed new category of hematopoietic precursor cells. Metcalf, D // Leukemia (08876924);Jan98, Vol. 12 Issue 1, p1 

    Hematopoietic precursor cells capable of forming blast colonies in vitro appear to be a distinct transit population between stem cells and lineage-committed progenitor cells because the cells in such blast colonies are mainly lineage-committed progenitor cells. It is proposed that blast...

  • Differential contributions of haematopoietic stem cells to foetal and adult haematopoiesis: insights from functional analysis of transcriptional regulators. Pina, C.; Enver, T. // Oncogene;10/15/2007, Vol. 26 Issue 47, p6750 

    An increasing number of molecules have been identified as candidate regulators of stem cell fates through their involvement in leukaemia or via post-genomic gene discovery approaches. A full understanding of the function of these molecules requires (1) detailed knowledge of the gene networks in...

  • Allogeneic bone marrow transplantation and donor lymphocyte infusion in a mouse model of irradiation-induced myelodysplastic/myeloproliferation syndrome (MD/MPS): evidence for a graft-versus-MD/MPS effect. Sprangers, B.; Van Wijmeersch, B.; Luyckx, A.; Sagaert, X.; De Somer, L.; Rutgeerts, O.; Lenaerts, C.; Landuyt, W.; Boeckx, N.; Dubois, B.; De Wolf-Peeters, C.; Waer, M.; Billiau, A. D. // Leukemia (08876924);Feb2009, Vol. 23 Issue 2, p340 

    The role of graft-versus-malignancy reactivity in the effects of allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusion (DLI) for myelodysplastic syndromes is as yet not well established. Clinical data are limited and animal models are scarce. Here, we report on the...

Share

Read the Article

Courtesy of AIRBUS FRANCE S.A.S.

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics